期刊文献+

埃克替尼治疗晚期非小细胞肺癌疗效评估 被引量:1

Ek for treatment of advanced non-small cell lung cancer curative effect evaluation
原文传递
导出
摘要 目的探讨分子靶向药物埃克替尼治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的临床疗效。方法选取我院2013-01—2014-12收治的晚期NSCLC患者60例,所有患者采用分子靶向药物埃克替尼的治疗方法进行治疗,观察患者的治疗效果。结果患者的完全缓解3例(5.00%),部分缓解15例(25.00%),稳定28例(46.67%),出现进展14例(23.33%)。客观缓解率为30.00%,疾病控制率为76.67%,一年内的生存率为55.00%。腹泻反应11例(18.33%),为I~Ⅱ级;皮疹反应29例(48.33%);转氨酶明显升高反应的有2例(3.33%),所有患者中都没有出现血液学毒性患者。结论晚期NSCLC患者采取分子靶向药物埃克替尼治疗的方法进行治疗,临床控制率相对较高,没有出现血液学毒性,药物治疗安全性相对较高,值得临床推广。 OBJECTIVE To study the molecular targeted drugs for ek, the clinical curative effect of treatment of advanced non-small cell lung cancer. METHODS Selection of our hospital in the late 60 patients with non-small-cell lung cancer (NSCLC) from 2013-01 to 2014-12, all of the patients using molecular targeted drugs for ek treatment for treatment, the treatment effect were observed. RESULTS The patients with complete remission in 3 patients (5.00%) and partial in 15 cases (25.00%), 28 cases (46.67%), stable progress in 14 cases (23.33%). Objective response rate was 30.00 %, the disease control rates is 76.67%, the survival rate of 55.00% a year. Reaction 11 cases (18.33%), diarrhea is I - II level; Rash reaction 29 eases (48.33%) ; Aminotransferase significantly higher reaction in 2 cases (3.33%), all of the patients did not appear in the patients with hematologic toxicity. CONCLUSION The patients with advanced nonsmall cell lung cancer treated with molecular targeted drugs for ek, the method of treatment, clinical control rates are rel- atively high, no hematology toxicity, medication safety is relative taller, worth clinical promotion.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2015年第B22期124-125,共2页 Chinese Journal of Cancer Prevention and Treatment
关键词 分子靶向药物 埃克替尼 晚期非小细胞肺癌 治疗效果 molecular targeted drugs Ek advanced non-small cell lung cancer treatment effect
  • 相关文献

参考文献4

二级参考文献32

  • 1KIM ES, HIRSH V, MOK T,et al. Gefitinib versus docetaxel in previously treated on-small cell lung cancer (INTEREST): a randomised phase Ⅲ trial [ J ]. Lancet, 2008, 372 ( 9652 ) : 1809 - 1818.
  • 2SHI Y, ZHANG L, LIU X, et al. Icotinib versus gefitinib in pre- viously treated advanced non-small-cell lung cancer (ICOGEN) : a randomised, double-blind phase 3 non-inferiority trial [ J ]. Lancet Oncol,2013,14 (10) :953 - 961.
  • 3SHEPHERD FA ,RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[ J]. N Engl J Med,2005,353(2) : 123 - 132.
  • 4LEE DH, PARK K, KIM JH,et al. Randomized Phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy [ J ]. Clin Cancer Res , 2010 ,16 ( 4 ) :1307 - 1314.
  • 5WANG J,CHEN K, BAI H, et al. Chemotherapy influence EG- FR mutation status for Chinese patients with regionally advanced non-small cell lung cancer [ J ]. J Clin Oncol, 2011,29 (suppl) : abstr 7031.
  • 6TARON M, ICHINOSE Y, ROSELL R, et al. Activating muta- tions in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas [ J ]. Clin Cancer Res, 2005,11(15) :5878 -5885.
  • 7GANDARA DR, GRIMMINGER P, MACK PC, et al. Associa- tion of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer[ J]. J Thorac 0ncol,2010,5 ( 12 ) : 1933 - 1938.
  • 8MOK TS, WU YL, THONGPRASERT S, et al. Gefitinib or car- boplatin-paclitaxel in pulmonary adenocarcinoma[ J ] . N Engl J Med, 2009, 361 (10) :947 - 957.
  • 9MAEMONDO M, INOUE A, KOBAYASHI K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [ J]. N Engl J Med,2010,362(25) :2380 -2388.
  • 10ZHOU C, WU YL, CHEN G, et al. Erlotinib versus chemother- apy as first-line treatment for patients with advanced EGFR muta- tion-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802): a muhicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol,2011,2(8) :735 -742.

共引文献25

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部